Kassberg Thomas Richard 4

What Happened
Thomas R. Kassberg, a director of Passage BIO, was granted a derivative award of 10,539 shares (reported as a stock option) on May 19, 2026. The Form 4 reports the acquisition as derivative securities with $0.00 reported consideration — i.e., no cash was exchanged at grant. This is a compensatory award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-19; filing date: 2026-05-21 (filed within the typical 2‑business‑day window).
• Amount: 10,539 derivative shares (stock option award); reported price/consideration: $0.00.
• Vesting: The option vests in full on the earlier of (i) one year after grant or (ii) the issuer’s 2027 Annual Meeting, subject to continuous service (footnote F1).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No immediate sale or cashless exercise reported — this is a grant/award, not a disposition.
• No indication of a 10b5‑1 plan or tax‑withholding shares in this filing.

Context
This is a standard board/compensation grant to a director and should be viewed as a routine issuance of equity‑based compensation rather than a market transaction expressing buy/sell sentiment. Because it’s a stock option award, value will depend on future vesting and any exercise price; the grant itself does not involve an immediate cash outlay or sale of shares.